-
公开(公告)号：US4851356A
公开(公告)日：1989-07-25
申请号：US72802
申请日：1987-07-14
IPC分类号： G01N33/574 , G01N33/577 , G01N33/76
CPC分类号： G01N33/76 , G01N33/57476 , G01N33/577 , Y10S436/804 , Y10S436/813 , Y10S436/814 , Y10S436/818 , Y10S436/823
摘要： An immunoassay for detecting and measuring hCG in a sample includes an antibody directed to the carboxy terminal portion of the .beta. subunit of hCG and a monoclonal antibody directed to a determinant on hCG at a locus sufficiently remote from the carboxy terminal portion of the .beta. subunit of hCG that both antibodies can simultaneously bind to hCG, wherein at least one of the antibodies is delectable when both are bound to hCG.In a presently preferred embodiment, an immunoassay for hCG or hCB.beta. in urine includes a purified, labeled or detectable serum-derived antibody directed to the carboxy-terminal portion of the .beta. subunit of hCG and a matrix-bound monoclonal antibody directed to a locus on the .beta. subunit sufficiently remote from the carboxy-terminal portion that both antibodies can simultaneously bind to hCG or hCG.beta..
摘要翻译： 用于检测和测量样品中的hCG的免疫测定包括针对hCG的β亚单位的羧基末端部分的抗体和针对hCG上的决定簇的单克隆抗体，其位于足够远离β-亚基的β亚基的羧基末端部分 两种抗体可以同时结合hCG的hCG，其中当二者结合hCG时，至少一种抗体是可选的。 在目前优选的实施方案中，尿中hCG或hCBβ的免疫测定包括针对hCG的β亚基的羧基末端部分的纯化的，标记的或可检测的血清衍生的抗体，以及针对基因座的基质结合的单克隆抗体 在足够远离羧基末端部分的β亚基上，两个抗体可以同时结合hCG或hCGβ。
-
公开(公告)号：US5976876A
公开(公告)日：1999-11-02
申请号：US763669
申请日：1996-12-11
CPC分类号： C07K16/26
摘要： This invention provides an antibody which specifically binds to hLH.beta.cf without cross-reacting with hLH, hLH.beta. or hCG.beta.cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No.12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH.beta.cf or hLH.beta.cf-related molecule in a sample.
摘要翻译： 本发明提供了一种特异性结合hLH beta cf而不与hLH，hLHβ或hCGβ比较的交叉反应的抗体。 在一个实施方案中，单克隆抗体命名为B505。 在另一个实施方案中，产生单克隆抗体B 505的杂交瘤细胞系称为ATCC登录号12000。 本发明提供了抗体的不同用途。 最后，本发明提供了一种测定样品中hLH beta cf或hLH beta cf相关分子量的方法。
-
公开(公告)号：US07034124B2
公开(公告)日：2006-04-25
申请号：US09404076
申请日：1999-09-23
IPC分类号： C07K16/00
CPC分类号： C07K16/26
摘要： This invention provides an antibody which specifically binds to hLHβcf without cross-reacting with hLH, hLHβ or hCGβcf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No. 12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLHβcf or hLHβcf-related molecule in a sample.
摘要翻译： 本发明提供了与hLHbetacf特异性结合而不与hLH，hLHbeta或hCGbetacf交叉反应的抗体。 在一个实施方案中，单克隆抗体命名为B505。 在另一个实施方案中，产生单克隆抗体B 505的杂交瘤细胞系被命名为ATCC登录号12000.本发明提供了抗体的不同用途。 最后，本发明提供了一种测定样品中hLHbetacf或hLHbetacf相关分子量的方法。
-
公开(公告)号：US06339143B1
公开(公告)日：2002-01-15
申请号：US08487949
申请日：1995-06-07
IPC分类号： C07K16/26 , G01N33/50 , G01N33/569 , G01N33/574 , G01N33/76
CPC分类号： C07K16/26 , G01N33/5091 , G01N33/56966 , G01N33/57492 , G01N33/76 , G01N2333/59 , G01N2333/705
摘要： This invention provides methods for detecting the presence of human malignant cells in a sample of tumor cells; determining whether a tumor present in a human subject is malignant; obtaining an enriched population of live human malignant cells; determining the amount of intact luteinizing hormone in a sample; determining the ovulatory stage of a subject; determining the amount of intact follicle stimulating hormone in a sample; determining the ovulatory stage of a subject; determining the amount of intact human chorionic gonadotropin in a sample; determining whether a subject is pregnant; determining the ovulatory stage of a subject; determining the amount of free &agr; subunit of human luteinizing hormone in a sample; determining whether a subject has a malignant tumor; determining the amount of nicked human chorionic gonadotropin in a sample; and determining the likelihood of a fetus's being afflicted with Down's syndrome.
摘要翻译： 本发明提供了用于检测肿瘤细胞样品中人恶性细胞存在的方法; 确定存在于人类受试者中的肿瘤是否是恶性的; 获得活的人类恶性细胞的富集群体; 确定样品中完整的黄体生成激素的量; 确定受试者的排卵期; 确定样品中完整的促卵泡激素的量; 确定受试者的排卵期; 确定样品中完整的人绒毛膜促性腺激素的量; 确定受试者是否怀孕; 确定受试者的排卵期; 测定样品中人黄体生成激素的游离α亚基的量; 确定受试者是否具有恶性肿瘤; 确定样品中切口的人绒毛膜促性腺激素的量; 并确定胎儿患有唐氏综合征的可能性。
-
公开(公告)号：US08163508B2
公开(公告)日：2012-04-24
申请号：US13180845
申请日：2011-07-12
IPC分类号： G01N33/53
CPC分类号： G01N33/76 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , G01N2800/368 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定样品中早期妊娠相关hCG的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
公开(公告)号：US07977104B2
公开(公告)日：2011-07-12
申请号：US11528883
申请日：2006-09-27
CPC分类号： G01N33/76 , C07K14/59 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , Y10S435/971 , Y10S436/811 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
-
7.发明授权Methods and reagents for determining the amount of hLHβ core fragment in a sample 失效用于测定样品中hLHbeta核心片段的量的方法和试剂公开(公告)号：US07655410B2
公开(公告)日：2010-02-02
申请号：US10361652
申请日：2003-02-10
CPC分类号： C07K16/36 , G01N33/76 , G01N2333/59 , G01N2800/52
摘要： The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLHβcf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLHβcf without substantially cross-reacting with hLH, hLHβ or hLHβcf, under conditions permitting formation of a complex between the antibody and hLHβcf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLHβcf in the sample; and (c) comprising the amount of hLHβcf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. AS described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.
摘要翻译： 本发明提供了一种通过确定来自受试者的样品中的hLHbetacf的量来预测围绝经期女性受试者的绝经发作的可能时机的方法，包括以下步骤：（a）使来自受试者的样品与抗体 其特异性结合hLHbetacf而不与hLH，hLHbeta或hLHbetacf基本上交叉反应，在允许形成抗体和hLHbetacf之间的复合物的条件下; （b）测量形成的复合物的量，从而确定样品中hLHetetf的量; （c）包含在步骤（b）中确定的受试者样品中的hLHbetacf的量与（i）已知绝经后女性受试者确定的量或（ii）从已知绝经前女性受试者确定的样品量，其中 与已知绝经后样品中hLHbetacf的量相似的样品中的hLHbetacf的量表明与绝经期的开始的时间接近，并且与已知绝经前样品中hLHbetacf的量相似的hLHbetacf的量表示与 该主题的更年期发病。 如本文所述，量是在一个或多个连续尿标本中浓度和浓度测量的模式。
-
公开(公告)号：US06927034B2
公开(公告)日：2005-08-09
申请号：US09311428
申请日：1999-05-13
IPC分类号： G01N33/53 , C07K16/26 , C12N15/02 , G01N33/577 , G01N33/76 , G01N33/543 , G01N33/537
CPC分类号： G01N33/76 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , G01N2800/368 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定样品中早期妊娠相关hCG的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
公开(公告)号：US08802381B2
公开(公告)日：2014-08-12
申请号：US13846172
申请日：2013-03-18
CPC分类号： G01N33/76 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , G01N2800/368 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定样品中早期妊娠相关hCG的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
公开(公告)号：US07993858B2
公开(公告)日：2011-08-09
申请号：US12807513
申请日：2010-09-07
CPC分类号： G01N33/76 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , G01N2800/368 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定样品中早期妊娠相关hCG的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.036 秒)
